Cytek Biosciences, Inc.
CTKBNASDAQHealthcare● Active
$4.04
$-0.05(-1.22%)
Market Cap$521736051
P/E Ratio—
52W High$6.18
52W Low$2.9
Cytek Biosciences, Inc. (CTKB) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · CTKB · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($0.07B) | ($0.01B) | ($0.01B) | $0.00B | $0.00B |
| Depreciation & Amort. | $0.01B | $0.01B | $0.01B | $0.01B | $0.00B |
| Stock-Based Comp. | $0.02B | $0.03B | $0.02B | $0.02B | $0.01B |
| Change in Working Capital | ($0.00B) | $0.01B | ($0.01B) | ($0.04B) | ($0.01B) |
| Net Cash from Operations | ($0.00B) | $0.03B | $0.01B | ($0.01B) | $0.00B |
| Investing Activities | |||||
| Capital Expenditure | ($0.00B) | ($0.00B) | ($0.00B) | ($0.01B) | ($0.00B) |
| Purchases of Investments | ($0.28B) | ($0.27B) | ($0.18B) | ($0.05B) | $0.00B |
| Sales of Investments | $0.29B | $0.20B | $0.13B | $0.00B | $0.00B |
| Net Cash from Investing | $0.01B | ($0.08B) | ($0.09B) | ($0.06B) | ($0.02B) |
| Financing Activities | |||||
| Common Stock Repurchased | ($0.02B) | ($0.02B) | ($0.04B) | $0.00B | $0.00B |
| Dividends Paid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Debt Issued / Repaid | $0.00B | $0.00B | ($0.00B) | $0.00B | ($0.00B) |
| Net Cash from Financing | ($0.01B) | ($0.02B) | ($0.04B) | $0.01B | $0.21B |
| Free Cash Flow | |||||
| Free Cash Flow | ($0.01B) | $0.02B | $0.00B | ($0.02B) | $0.00B |
| FCF Margin %(computed) | -4.35% | 10.90% | 0.24% | -13.47% | 0.21% |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · B
Explore more Cytek Biosciences, Inc. data
About Cytek Biosciences, Inc. (CTKB) Cash Flow Statement
Cytek Biosciences, Inc. generated operating cash flow of ($0.00B) and free cash flow of ($0.01B) for 2025 — a FCF margin of -4.35%. Capital expenditure was ($0.00B).
Frequently asked questions
CTKB · 4 questionsCytek Biosciences, Inc. generated free cash flow of ($0.01B) for 2025, down 140.1% year-over-year.
CTKB free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10